-
Media Release
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
-
Media Release
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
-
Media Release
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
-
Media Release
Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
-
Media Release
Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
-
Media Release
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
-
Media Release
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
-
Media Release
NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis
-
Media Release
NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis
-
Media Release
Multimedia Assets: Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media Release
Multimedia Assets: Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media Release
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder